Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhi
Lin, Yi-An
Kim, Soo-Young
Su, Lilly
Liu, Jinhuan
Kannan, Rangaramanujam M.
Kannan, Sujatha
-
Funding
Funding for this research was provided by:
National Institute of Child Health and Human Development (R01HD068562)
National Institute of Biomedical Imaging and Bioengineering (R01HD076901)
National Institute of Neurological Disorders and Stroke (R01NS093416)
- License Information
-
More Information
Article History
Received: 20 July 2020
Accepted: 5 October 2020
First Online: 25 October 2020
Ethics approval and consent to participate
: Experimental procedures were approved by the Johns Hopkins University Animal Care and Use Committee (IACUC).
: Not applicable.
: The authors (RMK, SK, and ZZ) have awarded and pending patents relating to the hydroxyl dendrimer platform for CNS and ocular disorders. RMK and SK are co-founders and have financial interests in Ashvattha Therapeutics Inc., and Orpheris Inc., start-ups translating dendrimer drug delivery platform. RMK and SK are board members of Ashvattha Therapeutics Inc.
